

# Saskia Middeldorp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2877041/publications.pdf>

Version: 2024-02-01

420  
papers

25,594  
citations

10986

71  
h-index

8866

145  
g-index

437  
all docs

437  
docs citations

437  
times ranked

20426  
citing authors

#	ARTICLE	IF	CITATIONS
1	Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. <i>New England Journal of Medicine</i> , 2013, 369, 1406-1415.	27.0	1,607
2	VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy. <i>Chest</i> , 2012, 141, e691S-e736S.	0.8	1,418
3	Incidence of venous thromboembolism in hospitalized patients with COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1995-2002.	3.8	1,227
4	Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 790-802.	27.0	778
5	Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 777-789.	27.0	712
6	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	27.0	692
7	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	27.0	687
8	Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. <i>Blood</i> , 2014, 124, 1968-1975.	1.4	662
9	Direct Thrombin Inhibitors. <i>New England Journal of Medicine</i> , 2005, 353, 1028-1040.	27.0	601
10	Oral Contraceptives and the Risk of Venous Thrombosis. <i>New England Journal of Medicine</i> , 2001, 344, 1527-1535.	27.0	507
11	ESHRE guideline: recurrent pregnancy loss. <i>Human Reproduction Open</i> , 2018, 2018, hoy004.	5.4	498
12	Aspirin plus Heparin or Aspirin Alone in Women with Recurrent Miscarriage. <i>New England Journal of Medicine</i> , 2010, 362, 1586-1596.	27.0	402
13	Heart rate variability and first cardiovascular event in populations without known cardiovascular disease: meta-analysis and dose-response meta-regression. <i>Europace</i> , 2013, 15, 742-749.	1.7	357
14	Simplified diagnostic management of suspected pulmonary embolism (the YEARS study): a prospective, multicentre, cohort study. <i>Lancet</i> , 2017, 390, 289-297.	13.7	357
15	Association between weight or body mass index and hand osteoarthritis: a systematic review. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 761-765.	0.9	332
16	American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. <i>Blood Advances</i> , 2018, 2, 3317-3359.	5.2	317
17	Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 92-128.	2.1	306
18	Fondaparinux for the Treatment of Superficial-Vein Thrombosis in the Legs. <i>New England Journal of Medicine</i> , 2010, 363, 1222-1232.	27.0	301

#	ARTICLE	IF	CITATIONS
19	Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. <i>Lancet, The</i> , 1999, 354, 2036-2040.	13.7	263
20	Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. <i>BMJ, The</i> , 2021, 375, n2400.	6.0	250
21	Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. <i>Blood</i> , 2009, 113, 5314-5322.	1.4	206
22	Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2019, 380, 1139-1149.	27.0	200
23	A Randomized Cross-over Study on the Effects of Levonorgestrel- and Desogestrel-containing Oral Contraceptives on the Anticoagulant Pathways. <i>Thrombosis and Haemostasis</i> , 2000, 84, 15-21.	3.4	199
24	Circulating Nucleosomes and Neutrophil Activation as Risk Factors for Deep Vein Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 147-151.	2.4	193
25	Trends in mortality related to pulmonary embolism in the European Region, 2000â€“15: analysis of vital registration data from the WHO Mortality Database. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 277-287.	10.7	192
26	The Incidence of Venous Thromboembolism in Family Members of Patients with Factor V Leiden Mutation and Venous Thrombosis. <i>Annals of Internal Medicine</i> , 1998, 128, 15.	3.9	179
27	Effects on Coagulation of Levonorgestrel- and Desogestrel-containing Low Dose Oral Contraceptives: a Cross-over Study. <i>Thrombosis and Haemostasis</i> , 2000, 84, 4-8.	3.4	178
28	COVID-19-associated coagulopathy and antithrombotic agentsâ€™ lessons after 1 year. <i>Lancet Haematology</i> , the, 2021, 8, e524-e533.	4.6	174
29	Mechanistic View of Risk Factors for Venous Thromboembolism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 563-568.	2.4	170
30	A Prospective Study of Asymptomatic Carriers of the Factor V Leiden Mutation To Determine the Incidence of Venous Thromboembolism. <i>Annals of Internal Medicine</i> , 2001, 135, 322.	3.9	169
31	Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. <i>Lancet, The</i> , 2016, 388, 2629-2641.	13.7	167
32	The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection. <i>European Journal of Epidemiology</i> , 2013, 28, 513-523.	5.7	166
33	Activation of coagulation system during air travel: a crossover study. <i>Lancet, The</i> , 2006, 367, 832-838.	13.7	162
34	Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 79-84.	3.8	159
35	Early migration of tibial components is associated with late revision. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2012, 83, 614-624.	3.3	159
36	Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. <i>Blood</i> , 2016, 127, 1417-1425.	1.4	156

#	ARTICLE	IF	CITATIONS
37	Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1439-1449.	3.4	154
38	Does thrombophilia testing help in the clinical management of patients?. <i>British Journal of Haematology</i> , 2008, 143, 321-335.	2.5	145
39	Increased Fibrinolytic Activity during Use of Oral Contraceptives Is Counteracted by an Enhanced Factor XI-independent down Regulation of Fibrinolysis. <i>Thrombosis and Haemostasis</i> , 2000, 84, 9-14.	3.4	144
40	Increased Risk for Fetal Loss in Carriers of the Factor V Leiden Mutation. <i>Annals of Internal Medicine</i> , 1999, 130, 736.	3.9	134
41	Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1474-1477.	3.8	130
42	Inherited Thrombophilia and Pregnancy Complications Revisited. <i>Obstetrics and Gynecology</i> , 2008, 112, 320-324.	2.4	127
43	Early proximal migration of cups is associated with late revision in THA. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2012, 83, 583-591.	3.3	123
44	The Absolute Risk of Venous Thrombosis after Air Travel: A Cohort Study of 8,755 Employees of International Organisations. <i>PLoS Medicine</i> , 2007, 4, e290.	8.4	118
45	Risk of Recurrent Venous Thrombosis in Homozygous Carriers and Double Heterozygous Carriers of Factor V Leiden and Prothrombin G20210A. <i>Circulation</i> , 2010, 121, 1706-1712.	1.6	115
46	Travel and venous thrombosis: a systematic review. <i>Journal of Internal Medicine</i> , 2007, 262, 615-634.	6.0	107
47	Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1673-1676.	3.8	106
48	Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. <i>Blood</i> , 2020, 136, 1433-1441.	1.4	106
49	Quality of life after pulmonary embolism: validation of the PEmbâ€œQoL Questionnaire. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 523-532.	3.8	103
50	Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000â€œ18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. <i>Lancet Respiratory Medicine</i> , 2021, 9, 33-42.	10.7	100
51	ISTH guidelines for antithrombotic treatment in COVIDâ€œ19. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 2214-2225.	3.8	100
52	Anticoagulant interventions in hospitalized patients with COVIDâ€œ19: A scoping review of randomized controlled trials and call for international collaboration. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 2958-2967.	3.8	98
53	Is Thrombophilia Testing Useful?. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 150-155.	2.5	96
54	Prothrombin 20210A Mutation. <i>Archives of Internal Medicine</i> , 2004, 164, 1932.	3.8	93

#	ARTICLE	IF	CITATIONS
55	Treatment for superficial thrombophlebitis of the leg. The Cochrane Library, 2013, , CD004982.	2.8	89
56	Hydroxychloroquine to Improve Pregnancy Outcome in Women with Antiphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. Seminars in Thrombosis and Hemostasis, 2017, 43, 562-571.	2.7	89
57	Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccines-Induced Immune Thrombotic Thrombocytopenia. JAMA Neurology, 2021, 78, 1314.	9.0	89
58	Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature. Journal of Thrombosis and Haemostasis, 2013, 11, 270-281.	3.8	88
59	Post-SARS-CoV-2 vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency. European Journal of Neurology, 2021, 28, 3656-3662.	3.3	84
60	Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19. JAMA - Journal of the American Medical Association, 2022, 327, 1247.	7.4	83
61	Thrombophilia and pregnancy complications: cause or association?. Journal of Thrombosis and Haemostasis, 2007, 5, 276-282.	3.8	82
62	Pregnancy and Venous Thromboembolism. Seminars in Thrombosis and Hemostasis, 2013, 39, 549-558.	2.7	81
63	Recurrent miscarriage and antiphospholipid antibodies: prognosis of subsequent pregnancy. Journal of Thrombosis and Haemostasis, 2010, 8, 2208-2213.	3.8	80
64	Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. The Cochrane Library, 2014, 2014, CD004734.	2.8	79
65	Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. Thrombosis and Haemostasis, 2016, 116, 651-658.	3.4	79
66	Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: is it effective?. Journal of Thrombosis and Haemostasis, 2011, 9, 473-480.	3.8	78
67	Abnormal uterine bleeding in VTE patients treated with rivaroxaban compared to vitamin K antagonists. Thrombosis Research, 2015, 136, 749-753.	1.7	78
68	Quality of life after pulmonary embolism as assessed with SF-36 and PEmb-QoL. Thrombosis Research, 2013, 132, 500-505.	1.7	77
69	Treatment of venous thromboembolism with vitamin K antagonists: patients' health state valuations and treatment preferences. Thrombosis and Haemostasis, 2004, 92, 1336-1341.	3.4	75
70	Thrombophilia and Venous Thromboembolism: Implications for Testing. Seminars in Thrombosis and Hemostasis, 2007, 33, 573-581.	2.7	75
71	Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception. Blood, 2011, 118, 2055-2061.	1.4	75
72	High rate of skin complications due to low-molecular-weight heparins in pregnant women. Journal of Thrombosis and Haemostasis, 2003, 1, 859-861.	3.8	73

#	ARTICLE	IF	CITATIONS
73	Risk of Cerebral Venous Thrombosis in Obese Women. <i>JAMA Neurology</i> , 2016, 73, 579.	9.0	72
74	Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial. <i>Lancet Haematology</i> , 2018, 5, e25-e33.	4.6	72
75	Inherited thrombophilia: a double-edged sword. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 1-9.	2.5	71
76	The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. <i>Thrombosis Research</i> , 2017, 150, 30-32.	1.7	70
77	The risk of pregnancy-related venous thromboembolism in women who are homozygous for factor V Leiden. <i>British Journal of Haematology</i> , 2001, 113, 553-555.	2.5	68
78	Treatment of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1554-1560.	3.8	66
79	In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1799-1805.	3.8	66
80	The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. <i>Thrombosis and Haemostasis</i> , 2016, 115, 285-290.	3.4	66
81	Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history of preeclampsia: a randomized trial. <i>American Journal of Obstetrics and Gynecology</i> , 2017, 216, 296.e1-296.e14.	1.3	66
82	Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. <i>Thrombosis and Haemostasis</i> , 2000, 84, 4-8.	3.4	66
83	A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. <i>Blood</i> , 2006, 108, 2604-2607.	1.4	65
84	Cerebral Venous Thrombosis and Thrombophilia: A Systematic Review and Meta-Analysis. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 913-927.	2.7	64
85	Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. <i>The Cochrane Library</i> , 2014, , CD001367.	2.8	64
86	Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. , 2009, , CD004734.		63
87	Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 943-948.	3.8	62
88	Early subsidence of shape-closed hip arthroplasty stems is associated with late revision. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2015, 86, 575-585.	3.3	62
89	Association Between Anemia and Cerebral Venous Thrombosis. <i>Stroke</i> , 2015, 46, 2735-2740.	2.0	61
90	Risk Factors for Cerebral Venous Thrombosis. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 622-631.	2.7	59

#	ARTICLE	IF	CITATIONS
91	Evidence-based approach to thrombophilia testing. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 31, 275-281.	2.1	58
92	A novel mutation in the F5 gene (factor V Amsterdam) associated with bleeding independent of factor V procoagulant function. <i>Blood</i> , 2015, 125, 1822-1825.	1.4	58
93	Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin. <i>Thrombosis and Haemostasis</i> , 2017, 117, 809-815.	3.4	58
94	The psychological impact of testing for thrombophilia: a systematic review. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1099-1104.	3.8	57
95	How I treat pregnancy-related venous thromboembolism. <i>Blood</i> , 2011, 118, 5394-5400.	1.4	56
96	Parenteral anticoagulation in ambulatory patients with cancer. , 2014, , CD006652.		56
97	Sex, thrombosis and inherited thrombophilia. <i>Blood Reviews</i> , 2014, 28, 123-133.	5.7	56
98	Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. , 2007, , CD006652.		55
99	Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. <i>Thrombosis and Haemostasis</i> , 2016, 116, 733-738.	3.4	55
100	Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusaiâ€‹<sc>VTE</sc> study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2018, 125, 1581-1589.	2.3	55
101	A lower risk of recurrent venous thrombosis in women compared with men is explained by sex-specific risk factors at time of first venous thrombosis in thrombophilic families. <i>Blood</i> , 2009, 114, 2031-2036.	1.4	54
102	Usefulness of standard computed tomography pulmonary angiography performed for acute pulmonary embolism for identification of chronic thromboembolic pulmonary hypertension: results of the InShape III study. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 731-738.	0.6	54
103	Aspirin or anticoagulants for the treatment of recurrent miscarriage in women without antiphospholipid syndrome. , 2005, , CD004734.		52
104	Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2011, , CD006652.		52
105	Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study. <i>Thrombosis Research</i> , 2020, 185, 13-19.	1.7	52
106	Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients. <i>Thrombosis Research</i> , 2020, 196, 308-312.	1.7	52
107	Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism. <i>Haematologica</i> , 2002, 87, 1068-73.	3.5	52
108	Hormone therapies and venous thromboembolism: where are we now?. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 257-266.	3.8	51



#	ARTICLE	IF	CITATIONS
109	Clinical Impact of Findings Supporting an Alternative Diagnosis on CT Pulmonary Angiography in Patients With Suspected Pulmonary Embolism. <i>Chest</i> , 2013, 144, 1893-1899.	0.8	51
110	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. <i>The Cochrane Library</i> , 2017, 2017, CD005158.	2.8	50
111	SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. <i>Thrombosis and Haemostasis</i> , 2021, 121, 982-991.	3.4	50
112	Pregnancy-related venous thromboembolism: Risk and the effect of thromboprophylaxis. <i>Thrombosis Research</i> , 2012, 129, 673-680.	1.7	49
113	Effects of Cancer on Platelets. <i>Seminars in Oncology</i> , 2014, 41, 311-318.	2.2	49
114	Heparin: From animal organ extract to designer drug. <i>Thrombosis Research</i> , 2008, 122, 753-762.	1.7	48
115	<i>In vivo</i> reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate. <i>British Journal of Haematology</i> , 2016, 172, 255-261.	2.5	48
116	Cancer and risk of cerebral venous thrombosis: a case-control study. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 90-95.	3.8	48
117	Low-molecular-weight heparin to prevent recurrent venous thromboembolism in pregnancy: Rationale and design of the Highlow study, a randomised trial of two doses. <i>Thrombosis Research</i> , 2016, 144, 62-68.	1.7	47
118	Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 118-129.	2.1	47
119	Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. <i>The Cochrane Library</i> , 2020, 2020, CD012852.	2.8	47
120	Antithrombotic therapy for pregnancy loss. <i>Human Reproduction Update</i> , 2013, 19, 656-673.	10.8	46
121	ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia - study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 208.	1.6	46
122	Thrombophilia: An Update. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 563-572.	2.7	45
123	Low-dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-analysis of the literature. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2075-2085.	3.8	45
124	Quality of life after pulmonary embolism: the development of the PEmb-QoL questionnaire. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1044-1046.	3.8	44
125	The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. <i>British Journal of Haematology</i> , 2002, 116, 625-631.	2.5	43
126	Thrombosis in women: what are the knowledge gaps in 2013?. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 180-191.	3.8	43



#	ARTICLE	IF	CITATIONS
127	Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1590-1596.	3.8	43
128	Sex differences in cerebral venous thrombosis: A systematic analysis of a shift over time. <i>International Journal of Stroke</i> , 2016, 11, 164-170.	5.9	43
129	Social aspects of genetic testing for factor V leiden mutation in healthy individuals and their importance for daily practice. <i>Thrombosis Research</i> , 2004, 113, 7-12.	1.7	42
130	Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance. <i>European Journal of Human Genetics</i> , 2008, 16, 14-17.	2.8	42
131	Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. <i>Blood</i> , 2018, 132, 2298-2304.	1.4	42
132	Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: Risk factors and effect on prognosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 234-241.	2.3	42
133	Testing for Inherited Thrombophilia in Recurrent Miscarriage. <i>Seminars in Reproductive Medicine</i> , 2011, 29, 540-547.	1.1	41
134	Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice. <i>Thrombosis Research</i> , 2017, 153, 101-107.	1.7	41
135	Non-invasive early exclusion of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: the InShape II study. <i>Thorax</i> , 2021, 76, 1002-1009.	5.6	41
136	Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1248-1263.	1.8	40
137	Postpartum Period Is a Risk Factor for Cerebral Venous Thrombosis. <i>Stroke</i> , 2019, 50, 501-503.	2.0	39
138	A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms. <i>Blood Advances</i> , 2021, 5, 113-121.	5.2	39
139	Treatment of superficial vein thrombosis to prevent deep vein thrombosis and pulmonary embolism: a systematic review. <i>Haematologica</i> , 2005, 90, 672-7.	3.5	39
140	Randomized trials of therapeutic heparin for COVID-19: A meta-analysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12638.	2.3	39
141	Safety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study. <i>Lancet Haematology</i> , 2020, 7, e884-e891.	4.6	38
142	Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS-CoV-2 vaccination. <i>European Journal of Neurology</i> , 2022, 29, 339-344.	3.3	38
143	A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. <i>Thrombosis and Haemostasis</i> , 2000, 84, 15-21.	3.4	38
144	Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutations. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1444-1448.	3.8	37

#	ARTICLE	IF	CITATIONS
145	Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 4.	8.6	37
146	A simple decision rule including Dâ€dimer to reduce the need for computed tomography scanning in patients with suspected pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1428-1435.	3.8	37
147	Treatment for superficial thrombophlebitis of the leg. <i>The Cochrane Library</i> , 2018, 2018, CD004982.	2.8	37
148	Frequency of Thrombocytopenia and Platelet Factor 4/Heparin Antibodies in Patients With Cerebral Venous Sinus Thrombosis Prior to the COVID-19 Pandemic. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 332.	7.4	37
149	Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications - No. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2073-2074.	3.8	36
150	Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1944-1951.	3.4	36
151	The cardiovascular risk profile of middleâ€aged women with polycystic ovary syndrome. <i>Clinical Endocrinology</i> , 2020, 92, 150-158.	2.4	36
152	Thrombophilia and New Anticoagulant Drugs. <i>Hematology American Society of Hematology Education Program</i> , 2004, 2004, 424-438.	2.5	35
153	The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. <i>Thrombosis and Haemostasis</i> , 2007, 98, 457-463.	3.4	35
154	Current practise of testing for inherited thrombophilia. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1979-1981.	3.8	35
155	Manifestations and clinical impact of pediatric inherited thrombophilia. <i>Blood</i> , 2015, 125, 1073-1077.	1.4	35
156	Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis. <i>Blood Advances</i> , 2020, 4, 5215-5225.	5.2	35
157	Predominance of leftâ€sided deep vein thrombosis and body weight. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2083-2084.	3.8	33
158	Evolution of Factor V Leiden. <i>Thrombosis and Haemostasis</i> , 2013, 110, 23-30.	3.4	33
159	Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation. <i>Thrombosis and Haemostasis</i> , 2013, 109, 633-642.	3.4	33
160	Everything the clinician needs to know about evidence-based anticoagulation in pregnancy. <i>Blood Reviews</i> , 2019, 33, 82-97.	5.7	33
161	Imaging for the exclusion of pulmonary embolism in pregnancy. <i>The Cochrane Library</i> , 2017, 2017, CD011053.	2.8	32
162	Effect of the selective serotonin reuptake inhibitor paroxetine on platelet function is modified by a SLC6A4 serotonin transporter polymorphism. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 2168-2174.	3.8	31

#	ARTICLE	IF	CITATIONS
163	Clinical implications of incidental venous thromboembolism in cancer patients. <i>European Respiratory Journal</i> , 2020, 55, 1901697.	6.7	31
164	Hypertensive Complications of Pregnancy and Risk of Venous Thromboembolism. <i>Hypertension</i> , 2020, 75, 781-787.	2.7	31
165	Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. <i>Thrombosis and Haemostasis</i> , 2009, 101, 465-470.	3.4	30
166	AQUILA: assessment of quality in lower limb arthroplasty. An expert Delphi consensus for total knee and total hip arthroplasty. <i>BMC Musculoskeletal Disorders</i> , 2011, 12, 173.	1.9	30
167	Abdominal adiposity largely explains associations between insulin resistance, hyperglycemia and subclinical atherosclerosis: The NEO study. <i>Atherosclerosis</i> , 2013, 229, 423-429.	0.8	30
168	Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. <i>Thrombosis and Haemostasis</i> , 2000, 84, 9-14.	3.4	29
169	Thrombophilia in Childhood: To Test or Not to Test. <i>Seminars in Thrombosis and Hemostasis</i> , 2011, 37, 794-801.	2.7	28
170	Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. <i>The Cochrane Library</i> , 2013, , CD006503.	2.8	28
171	Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases. <i>Blood Advances</i> , 2020, 4, 6291-6297.	5.2	28
172	Pregnancy Failure and Heritable Thrombophilia. <i>Seminars in Hematology</i> , 2007, 44, 93-97.	3.4	27
173	Incidence of postpartum haemorrhage in women receiving therapeutic doses of low-molecular-weight heparin: results of a retrospective cohort study. <i>BMJ Open</i> , 2011, 1, e000257-e000257.	1.9	27
174	Complications of pregnancy and labour in women with Klippel-Feil syndrome: a nationwide cross-sectional study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1780-1788.	2.3	27
175	Prognostic value of cardiovascular parameters in computed tomography pulmonary angiography in patients with acute pulmonary embolism. <i>European Respiratory Journal</i> , 2018, 52, 1702611.	6.7	27
176	Sex matters: Practice 5P's when treating young women with venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1417-1429.	3.8	27
177	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 297-303.	3.8	27
178	Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 935-938.	3.8	26
179	RSA prediction of high failure rate for the uncoated Interax TKA confirmed by meta-analysis. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2012, 83, 142-147.	3.3	26
180	Genes associated with venous thromboembolism in colorectal cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 293-302.	3.8	26

#	ARTICLE	IF	CITATIONS
181	Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. <i>Blood Advances</i> , 2020, 4, 2351-2365.	5.2	26
182	Absolute risk of venous and arterial thromboembolism in thrombophilic families is not increased by high thrombin-activatable fibrinolysis inhibitor (TAFI) levels. <i>Thrombosis and Haemostasis</i> , 2008, 100, 38-44.	3.4	25
183	Explanations for coagulation activation after air travel. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 971-978.	3.8	25
184	Time to conception and time to live birth in women with unexplained recurrent miscarriage. <i>Human Reproduction</i> , 2014, 29, 1146-1152.	0.9	25
185	Clinical Course of Cerebral Venous Thrombosis in Adult Acute Lymphoblastic Leukemia. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 1679-1684.	1.6	25
186	Transgender patients and the role of the coagulation clinician. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1790-1797.	3.8	25
187	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. <i>Stroke</i> , 2021, 52, 2096-2105.	2.0	25
188	Hematoma Expansion and Clinical Outcomes in Patients With Factor-Xa Inhibitor-Related Atraumatic Intracerebral Hemorrhage Treated Within the ANNEXA-4 Trial Versus Real-World Usual Care. <i>Stroke</i> , 2022, 53, 532-543.	2.0	25
189	Thrombophilia testing for prevention of recurrent venous thromboembolism. <i>The Cochrane Library</i> , 2012, 12, CD007069.	2.8	24
190	Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM). <i>Systematic Reviews</i> , 2014, 3, 69.	5.3	24
191	Sex-specific differences in the presenting location of a first venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1344-1350.	3.8	24
192	Pulmonary embolism at autopsy in cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1228-1235.	3.8	24
193	Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 2373-2376.	3.8	23
194	Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term. <i>British Journal of Haematology</i> , 2012, 158, 433-441.	2.5	23
195	Number and sequence of preceding miscarriages and maternal age for the prediction of antiphospholipid syndrome in women with recurrent miscarriage. <i>Fertility and Sterility</i> , 2013, 99, 188-192.	1.0	23
196	The IDEAL DVT study, individualised duration elastic compression therapy against long-term duration of therapy for the prevention of post-thrombotic syndrome: protocol of a randomised controlled trial. <i>BMJ Open</i> , 2014, 4, e005265-e005265.	1.9	23
197	Clinical and economic impact of compression in the acute phase of deep vein thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1555-1563.	3.8	23
198	Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect: a retrospective analysis. <i>Blood Coagulation and Fibrinolysis</i> , 2001, 12, 713-720.	1.0	22

#	ARTICLE	IF	CITATIONS
199	Treatment for superficial thrombophlebitis of the leg. , 2007, , CD004982.		22
200	TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial. BMC Pediatrics, 2017, 17, 122.	1.7	22
201	Contemporary best practice in the management of pulmonary embolism during pregnancy. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662091422.	2.6	22
202	Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c. Thrombosis and Haemostasis, 2007, 98, 1040-1044.	3.4	22
203	Home parenteral nutrition-associated thromboembolic and bleeding events: results of a cohort study of 236 individuals. Journal of Thrombosis and Haemostasis, 2016, 14, 1364-1373.	3.8	21
204	How I treat venous thromboembolism in pregnancy. Blood, 2020, 136, 2133-2142.	1.4	21
205	Management of Cerebral Venous Thrombosis Due to Adenoviral <sc>COVID</sc>-19 Vaccination. Annals of Neurology, 2022, 92, 562-573.	5.3	21
206	Oral contraceptives and the risk of venous thromboembolism. Gender Medicine, 2005, 2, S3-S9.	1.4	20
207	Different risk of deep vein thrombosis and pulmonary embolism in carriers with factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. Haematologica, 2010, 95, 1030-1033.	3.5	20
208	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. The Cochrane Library, 2011, , CD005158.	2.8	20
209	The Effect of Prothrombotic Blood Abnormalities on Risk of Deep Vein Thrombosis in Users of Hormone Replacement Therapy. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, E106-E113.	1.7	20
210	Direct Oral Anticoagulants and Women. Seminars in Thrombosis and Hemostasis, 2016, 42, 789-797.	2.7	20
211	Interaction of Hereditary Thrombophilia and Traditional Cardiovascular Risk Factors on the Risk of Arterial Thromboembolism. Circulation: Cardiovascular Genetics, 2016, 9, 79-85.	5.1	20
212	Lower prevalence of subsegmental pulmonary embolism after application of the <sc>YEARS</sc> diagnostic algorithm. British Journal of Haematology, 2018, 183, 629-635.	2.5	20
213	Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID) Tj ETQq1 1 0,784314 rgBT /Overl Trials, 2021, 22, 202.	1.6	19
214	Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. Thrombosis and Haemostasis, 2022, 122, 998-1005.	3.4	19
215	Age-Stratified Risk of Cerebral Venous Sinus Thrombosis After SARS-CoV-2 Vaccination. Neurology, 2022, 98, .	1.1	19
216	Editorial. Cardiovascular Research, 1999, 41, 21-24.	3.8	18

#	ARTICLE	IF	CITATIONS
217	Nasal Levels of Antimicrobial Peptides in Allergic Asthma Patients and Healthy Controls: Differences and Effect of a Short 1,25(OH) <sub>2</sub> Vitamin D <sub>3</sub> Treatment. PLoS ONE, 2015, 10, e0140986.	2.5	18
218	Influence of World Thrombosis Day on digital information seeking on venous thrombosis: a Google Trends study. Journal of Thrombosis and Haemostasis, 2016, 14, 2325-2328.	3.8	18
219	Sex-specific differences in the distal versus proximal presenting location of acute deep vein thrombosis. Thrombosis Research, 2018, 172, 74-79.	1.7	18
220	Coronary artery calcification in middle-aged women with premature ovarian insufficiency. Clinical Endocrinology, 2019, 91, 314-322.	2.4	18
221	Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 569-581.	2.3	18
222	Prediction of chronic thromboembolic pulmonary hypertension with standardised evaluation of initial computed tomography pulmonary angiography performed for suspected acute pulmonary embolism. European Radiology, 2022, 32, 2178-2187.	4.5	18
223	High levels of protein C are determined by PROCRA haplotype 3. Journal of Thrombosis and Haemostasis, 2011, 9, 969-976.	3.8	17
224	Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thrombosis and Haemostasis, 2016, 116, 155-161.	3.4	17
225	Endogenous sex hormones and risk of venous thromboembolism in young women. Journal of Thrombosis and Haemostasis, 2019, 17, 1297-1304.	3.8	17
226	Thrombophilia, Thrombosis and Thromboprophylaxis in Pregnancy: For What and in Whom?. Hamostaseologie, 2022, 42, 054-064.	1.9	17
227	Thrombophilia testing for prevention of recurrent venous thromboembolism. , 2009, , CD007069.		16
228	Successful co-administration of dabigatran etexilate and protease inhibitors ritonavir/lopinavir in a patient with atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 836-838.	3.4	16
229	The risk of venous thrombosis after air travel: contribution of clinical risk factors. British Journal of Haematology, 2014, 165, 412-413.	2.5	16
230	Advances in the Treatment of Cerebral Venous Thrombosis. Current Treatment Options in Neurology, 2014, 16, 299.	1.8	16
231	Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Thrombosis and Haemostasis, 2016, 116, 1159-1164.	3.4	16
232	Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. , 2007, , CD005158.		15
233	Definition of bleeding events in studies evaluating prophylactic antithrombotic therapy in pregnant women: A systematic review and a proposal from the ISTH SSC. Journal of Thrombosis and Haemostasis, 2019, 17, 1979-1988.	3.8	15
234	Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials. Thrombosis Research, 2017, 149, 29-37.	1.7	14



#	ARTICLE	IF	CITATIONS
235	Whole exome sequencing in thrombophilic pedigrees to identify genetic risk factors for venous thromboembolism. PLoS ONE, 2017, 12, e0187699.	2.5	14
236	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. Thrombosis and Haemostasis, 2021, 121, 1097-1106.	3.4	14
237	Antithrombotic therapy to prevent recurrent pregnancy loss in antiphospholipid syndrome—What is the evidence?. Journal of Thrombosis and Haemostasis, 2021, 19, 1174-1185.	3.8	14
238	Monitoring of unfractionated heparin in critically ill patients. Netherlands Journal of Medicine, 2013, 71, 466-71.	0.5	14
239	Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination. Journal of Thrombosis and Thrombolysis, 2000, 9, 263-269.	2.1	13
240	Treatment for superficial thrombophlebitis of the leg. , 2012, , CD004982.		13
241	Cancer and Venous Thrombosis: Current Comprehensions and Future Perspectives. Seminars in Thrombosis and Hemostasis, 2013, 39, 507-514.	2.7	13
242	Anticoagulation in pregnancy complications. Hematology American Society of Hematology Education Program, 2014, 2014, 393-399.	2.5	13
243	Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH: reply. Journal of Thrombosis and Haemostasis, 2017, 15, 195-197.	3.8	13
244	Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study. Thrombosis Research, 2017, 160, 76-82.	1.7	13
245	Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis. Lancet Haematology, the, 2018, 5, e512-e519.	4.6	13
246	Extensive pulmonary perfusion defects compatible with microthrombosis and thromboembolic disease in severe Covid-19 pneumonia. Thrombosis Research, 2020, 196, 135-137.	1.7	13
247	Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants. Thrombosis and Haemostasis, 2020, 120, 899-911.	3.4	13
248	Gut microbiota and their metabolites in cardiovascular disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101492.	4.7	13
249	Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials. Journal of Thrombosis and Haemostasis, 2021, 19, 3080-3089.	3.8	13
250	Anticoagulants for the prevention and treatment of catheter-related thrombosis in adults and children on parenteral nutrition: a systematic review and critical appraisal. Blood Transfusion, 2017, 15, 369-377.	0.4	13
251	Protein S type III deficiency is no risk factor for venous and arterial thromboembolism in 168 thrombophilic families: a retrospective study. Blood Coagulation and Fibrinolysis, 2005, 16, 135-140.	1.0	12
252	Treatment for superficial thrombophlebitis of the leg. , 2007, , CD004982.		12



#	ARTICLE	IF	CITATIONS
253	The incidence of venous thromboembolism in commercial airline pilots: a cohort study of 2630 pilots. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1260-1265.	3.8	12
254	International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 3-27.	3.8	12
255	Unselected women with elevated levels of factor VIII:C or homocysteine are not at increased risk for obstetric complications. <i>Thrombosis and Haemostasis</i> , 2004, 92, 787-790.	3.4	11
256	Skin reactions due to low molecular weight heparin in pregnancy: a strategic dilemma. <i>Archives of Gynecology and Obstetrics</i> , 2005, 271, 163-165.	1.7	11
257	Hyperhomocysteinemia is not a risk factor for venous and arterial thrombosis, and is associated with elevated factor VIII levels. <i>Thrombosis Research</i> , 2008, 123, 244-250.	1.7	11
258	Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia. , 2008, , CD006503.		11
259	Increased sperm count may account for high population frequency of factor V Leiden. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 513-516.	3.8	11
260	Low-molecular-weight heparins have no place in recurrent miscarriage: Debate " For the motion. <i>Thrombosis Research</i> , 2011, 127, S105-S109.	1.7	11
261	Treatment of Lower Extremity Superficial Thrombophlebitis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 729.	7.4	11
262	Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. <i>Thrombosis and Haemostasis</i> , 2018, 118, 174-181.	3.4	11
263	Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 689-695.	2.3	11
264	Thrombosis and hemostasis health in pregnancy: Registries from the International Society on Thrombosis and Haemostasis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 607-614.	2.3	11
265	Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives: Systematic review and meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1158-1165.	3.8	11
266	Development in anticoagulant therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 145-154.	4.4	10
267	Associations between high factor VIII and low free protein S levels with traditional arterial thrombotic risk factors and their risk on arterial thrombosis: Results from a retrospective family cohort study. <i>Thrombosis Research</i> , 2010, 126, e249-e254.	1.7	10
268	Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2011, , CD006652.		10
269	Recommendations for prophylaxis of pregnancy-related venous thromboembolism in carriers of inherited thrombophilia. Comment on the 2012 ACCP guidelines: a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1782-1784.	3.8	10
270	Introduction to the analysis of next generation sequencing data and its application to venous thromboembolism. <i>Thrombosis and Haemostasis</i> , 2015, 114, 920-932.	3.4	10

#	ARTICLE	IF	CITATIONS
271	Thrombophilic risk of individuals with rare compound factor V Leiden and prothrombin G20210A polymorphisms: an international case series of 100 individuals. <i>European Journal of Haematology</i> , 2016, 97, 353-360.	2.2	10
272	No added value of the age-adjusted D-dimer cut-off to the YEARS algorithm in patients with suspected pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2317-2324.	3.8	10
273	Sex-specific performance of pre-imaging diagnostic algorithms for pulmonary embolism. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 858-865.	3.8	10
274	Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3008-3017.	3.8	10
275	How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. <i>Blood Advances</i> , 2021, 5, 4721-4726.	5.2	10
276	Platelet transfusion in patients with aneurysmal subarachnoid hemorrhage is associated with poor clinical outcome. <i>Scientific Reports</i> , 2020, 10, 856.	3.3	10
277	How to Decide on the Optimal Duration of Anticoagulant Therapy in Carriers of the Factor V Leiden Mutation. <i>Thrombosis and Haemostasis</i> , 2000, 84, 740-741.	3.4	9
278	The use of LMWH in pregnancies at risk: new evidence or perception?. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 788-789.	3.8	9
279	Inherited Thrombophilias. <i>Obstetrics and Gynecology Clinics of North America</i> , 2006, 33, 357-374.	1.9	9
280	Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 223-230.	2.3	9
281	Factor XIII Val34Leu and the risk of venous thromboembolism in factor V Leiden carriers. <i>British Journal of Haematology</i> , 2000, 111, 118-121.	2.5	9
282	The risk of venous and arterial thrombosis in hyperhomocysteinaemia is low and mainly depends on concomitant thrombophilic defects. <i>Thrombosis and Haemostasis</i> , 2007, 98, 457-63.	3.4	9
283	Post-thrombotic syndrome after upper extremity deep vein thrombosis: An international Delphi consensus study. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1880-1886.	3.8	9
284	High thrombin-activatable fibrinolysis inhibitor levels may protect against recurrent fetal loss. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 903-906.	3.8	8
285	Thrombin activatable fibrinolysis inhibitor (TAFI) is not associated with fetal loss, a retrospective study. <i>Thrombosis Research</i> , 2009, 123, 511-514.	1.7	8
286	Risk of cardiovascular disease in double heterozygous carriers and homozygous carriers of <i>F5</i> R506Q (factor V Leiden) and <i>F2</i> (prothrombin) G20210A: a retrospective family cohort study. <i>British Journal of Haematology</i> , 2011, 153, 134-136.	2.5	8
287	Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg. <i>Annals of Hematology</i> , 2012, 91, 103-107.	1.8	8
288	Placental expression of heparan sulfate 3-O-sulfotransferase-3A1 in normotensive and pre-eclamptic pregnancies. <i>Placenta</i> , 2015, 36, 1218-1224.	1.5	8

#	ARTICLE	IF	CITATIONS
289	The impact of a male or female thrombotic family history on contraceptive counseling: a cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1741-1748.	3.8	8
290	Growth differentiation factor-15 for prediction of bleeding in cancer patients. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 20, 138.	3.8	8
291	Acquired and Inherited Thrombophilic Factors and the Risk for Residual Venous Thrombosis. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2003, 33, 192-196.	0.3	7
292	Epidemiology of hormone-related venous thromboembolism. <i>Thrombosis Research</i> , 2009, 123, S65-S69.	1.7	7
293	Duration of anticoagulation for venous thromboembolism. <i>BMJ: British Medical Journal</i> , 2011, 342, d2758-d2758.	2.3	7
294	Prevalence of factor V Leiden and G20210A prothrombin mutation in the Dutch Famine Birth Cohort: A possible survival advantage?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 399-401.	3.4	7
295	The accuracy of D-dimer testing in suspected pulmonary embolism varies with the Wells score. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2630-2632.	3.8	7
296	Acute lymphoblastic leukemia during the third trimester of pregnancy. <i>Leukemia and Lymphoma</i> , 2018, 59, 1274-1276.	1.3	7
297	Treatment of Lower Extremity Superficial Thrombophlebitis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2367.	7.4	7
298	Creatine kinase is associated with blood pressure during pregnancy. <i>Journal of Hypertension</i> , 2019, 37, 1467-1474.	0.5	7
299	Women's health in The BMJ: a data science history. <i>BMJ Open</i> , 2020, 10, e039759.	1.9	7
300	Current practice patterns of outpatient management of acute pulmonary embolism: A post-hoc analysis of the YEARS study. <i>Thrombosis Research</i> , 2020, 193, 60-65.	1.7	7
301	Prognostic characteristics and body mass index in patients with pulmonary embolism: does size matter?. <i>ERJ Open Research</i> , 2020, 6, 00163-2019.	2.6	7
302	Progress of the ALIFE2 study: A dynamic road towards more evidence. <i>Thrombosis Research</i> , 2020, 190, 39-44.	1.7	7
303	Routine screening for pulmonary embolism in COVID-19 patients at the emergency department: impact of D-dimer testing followed by CTPA. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 1068-1073.	2.1	7
304	Pregnancy outcomes in women with Budd-Chiari syndrome or portal vein thrombosis: a multicentre retrospective cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 608-617.	2.3	7
305	Natural Course of the Subsequent Pregnancy after a Single Loss in Women with and without the Factor V Leiden or Prothrombin 20210A Mutations.. <i>Blood</i> , 2006, 108, 275-275.	1.4	7
306	A toolkit for the collection of thrombosis-related data elements in COVID-19 clinical studies. <i>Blood Advances</i> , 2020, 4, 6259-6273.	5.2	7

#	ARTICLE	IF	CITATIONS
307	Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1376-1384.	3.8	7
308	ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukinâ€6. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12630.	2.3	7
309	New studies of low-molecular-weight heparin in pregnancy. <i>Thrombosis Research</i> , 2015, 135, S26-S29.	1.7	6
310	Clinical outcome of patients with a vitamin K antagonistâ€associated bleeding treated with prothrombin complex concentrate. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2018, 2, 77-84.	2.3	6
311	Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of highâ€and lowâ€dose rivaroxaban with aspirin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 308-313.	2.3	6
312	Diagnostic accuracy of four different D-dimer assays: A post-hoc analysis of the YEARS study. <i>Thrombosis Research</i> , 2021, 201, 18-22.	1.7	6
313	Differences in thrombin and plasmin generation potential between East African and Western European adults: The role of genetic and nonâ€genetic factors. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1089-1105.	3.8	6
314	Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. <i>Thrombosis and Haemostasis</i> , 2009, 101, 465-70.	3.4	6
315	Hyperemesis gravidarum and vitamin K deficiency: a systematic review. <i>British Journal of Nutrition</i> , 2022, 128, 30-42.	2.3	5
316	Quantitative trait locus for protein C in a family with thrombophilia. <i>Thrombosis and Haemostasis</i> , 2011, 105, 199-201.	3.4	4
317	Reproducibility of exhaled nitric oxide measurements in overweight and obese adults. <i>BMC Research Notes</i> , 2014, 7, 775.	1.4	4
318	Coagulation activation during air travel is not initiated via the extrinsic pathway. <i>British Journal of Haematology</i> , 2015, 169, 903-905.	2.5	4
319	No association between <i>rs11209102</i> genetic variants and deep venous thrombosis. <i>British Journal of Haematology</i> , 2015, 169, 301-304.	2.5	4
320	Long-term vs Short-term Therapy With Vitamin K Antagonists for Symptomatic Venous Thromboembolism. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 72.	7.4	4
321	Oral contraceptive use is a provoking factor for venous thromboembolism. <i>BMJ: British Medical Journal</i> , 2017, 357, j2073.	2.3	4
322	Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. <i>The Cochrane Library</i> , 0, , .	2.8	4
323	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. <i>Thrombosis Research</i> , 2018, 163, 128-131.	1.7	4
324	Efficacy and safety of edoxaban in clinically relevant subgroups: results from the Hokusai VTE Cancer randomized trial. <i>Thrombosis Research</i> , 2018, 164, S194.	1.7	4

#	ARTICLE	IF	CITATIONS
325	The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients. <i>Thrombosis Research</i> , 2018, 170, 75-83.	1.7	4
326	Development of a Plasma-Based Assay to Measure the Susceptibility of Factor V to Inhibition by the C-Terminus of TFP1±. <i>Thrombosis and Haemostasis</i> , 2020, 120, 055-064.	3.4	4
327	Thromboembolic and bleeding complications in patients with oesophageal cancer. <i>British Journal of Surgery</i> , 2020, 107, 1324-1333.	0.3	4
328	Pregnancy in women with an inferior vena cava filter: a tertiary center experience and overview of the literature. <i>Blood Advances</i> , 2021, 5, 4044-4053.	5.2	4
329	ACTION-1: study protocol for a randomised controlled trial on ACT-guided heparinization during open abdominal aortic aneurysm repair. <i>Trials</i> , 2021, 22, 639.	1.6	4
330	Tranexamic acid to prevent operation in chronic subdural haematoma (TORCH): study protocol for a randomised placebo-controlled clinical trial. <i>Trials</i> , 2022, 23, 56.	1.6	4
331	Risk factors of arterial cardiovascular complications in patients with prior venous thromboembolism. <i>Netherlands Journal of Medicine</i> , 2011, 69, 27-30.	0.5	4
332	A Rebuttal: Counseling Pregnant Women with Factor V Leiden Homozygosity: Use Absolute instead of Relative Risk. <i>Thrombosis and Haemostasis</i> , 2002, 87, 360-361.	3.4	3
333	Prevalence of JAK2V617F mutation in women with unexplained recurrent miscarriage. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2837-2839.	3.8	3
334	Safety of prothrombin complex concentrate in healthy subjects. <i>British Journal of Haematology</i> , 2017, 176, 664-666.	2.5	3
335	Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial. <i>Thrombosis Research</i> , 2018, 164, S223.	1.7	3
336	Thromboprophylaxis in pregnant women: For whom and which LMWH dosage?. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1401-1403.	3.8	3
337	Creatine kinase and blood pressure in women with a history of early-onset preeclampsia. <i>Pregnancy Hypertension</i> , 2019, 15, 118-122.	1.4	3
338	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. <i>Lancet Rheumatology</i> , The, 2020, 2, e735-e736.	3.9	3
339	Sex-specific differences in clot resolution 3 weeks after acute pulmonary embolism managed with anticoagulants: A substudy of the EINSTEIN-PE study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1759-1763.	3.8	3
340	Home Treatment Compared to Initial Hospitalization in Normotensive Patients with Acute Pulmonary Embolism in the Netherlands: A Cost Analysis. <i>Thrombosis and Haemostasis</i> , 2022, 122, 427-433.	3.4	3
341	Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12566.	2.3	3
342	Low absolute risk of venous and arterial thrombosis in hyperhomocysteinaemia: A prospective family cohort study in asymptomatic subjects. <i>Thrombosis and Haemostasis</i> , 2009, 101, 209-212.	3.4	3

#	ARTICLE	IF	CITATIONS
343	Interm Report of the Highlow Study: A Randomized Controlled Trial Comparing Two Doses of Low Molecular Weight Heparin for the Prevention of Pregnancy-Associated Recurrent Venous Thromboembolism. <i>Blood</i> , 2016, 128, 1444-1444.	1.4	3
344	Splanchnic vein thrombosis-related mortality in the Veneto region (Italy), 2008–2019: Retrospective analysis of epidemiological data. <i>Thrombosis Research</i> , 2022, 209, 41-46.	1.7	3
345	Women's representation in venous thromboembolism randomized trials and registries: The illustrative example of direct oral anticoagulants for acute treatment. <i>Contemporary Clinical Trials</i> , 2022, 115, 106714.	1.8	3
346	Factor XIII Val34Leu and the risk of venous thromboembolism in factor V Leiden carriers. <i>British Journal of Haematology</i> , 2000, 111, 118-121.	2.5	2
347	Session 18: Miscarriage: Treatment and Prognostic Factors. <i>Human Reproduction</i> , 2010, 25, i28-i30.	0.9	2
348	Prophylaxis with low-dose low molecular weight heparin during pregnancy and the puerperium: is it effective? Reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1272-1273.	3.8	2
349	Low-molecular-weight heparin and pregnancy, when the dose does it: a nephrologist's opinion: reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2129-2130.	3.8	2
350	Screening for Antiphospholipid Antibodies in Women With Pregnancy Complications: Response. <i>Chest</i> , 2012, 142, 545-546.	0.8	2
351	The tropics and the crime they did not commit. <i>Infection</i> , 2013, 41, 275-277.	4.7	2
352	Factor V Leiden is associated with increased sperm count. <i>Human Reproduction</i> , 2017, 32, 2332-2339.	0.9	2
353	Venous thromboembolism after induced abortion: the shorter the pregnancy, the lower the risk?. <i>Lancet Haematology</i> , 2018, 5, e271-e272.	4.6	2
354	An anticoagulant that does not cause bleeding – an abrupt stop on the road to the Holy Grail. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2019-2021.	3.8	2
355	Short-term prognosis of breakthrough venous thromboembolism in anticoagulated patients. <i>Thrombosis Research</i> , 2020, 187, 125-130.	1.7	2
356	Aspirin and Aspirin Combined with Low-Molecular-Weight Heparin in Women with Unexplained Recurrent Miscarriage: a Randomized Controlled Multicenter Trial (ALIFE Study).. <i>Blood</i> , 2009, 114, 488-488.	1.4	2
357	Elevated Levels of Circulating Nucleosomes Are Not Associated with Venous Thrombosis or Neutrophil Activation in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 274-274.	1.4	2
358	A rebuttal: Counseling pregnant women with factor V Leiden homozygosity: use absolute instead of relative risks. <i>Thrombosis and Haemostasis</i> , 2002, 87, 360-1; author reply 361.	3.4	2
359	Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12748.	2.3	2
360	Acute myocardial infarction with large bilateral intracoronary thrombi in a young patient with the prothrombin 20210 G→A mutation. , 1998, 44, 427-430.		1



#	ARTICLE	IF	CITATIONS
361	Factor V:Q<sup>506</sup>Mutation-Resistance to Activated Protein C (APC): Clinical Implications with Respect to Family Screening. <i>Seminars in Thrombosis and Hemostasis</i> , 1998, 24, 363-366.	2.7	1
362	Hereditary and Acquired Thrombophilia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2000, 21, 467-476.	2.1	1
363	O12 Risk of early post-partum hemorrhage in women receiving therapeutic doses of low molecular weight heparin. <i>Thrombosis Research</i> , 2009, 123, S134.	1.7	1
364	Women admitted to hospital during pregnancy have increased risk of venous thromboembolism that persists up to 28 days postdischarge. <i>Evidence-based Nursing</i> , 2014, 17, 103-103.	0.2	1
365	Live birth rate and time to live birth in women with unexplained recurrent miscarriage with or without inherited thrombophilia. <i>Fertility and Sterility</i> , 2014, 102, e82.	1.0	1
366	Direct factor Xa inhibitor edoxaban: from bench to clinical practice. <i>Expert Review of Hematology</i> , 2015, 8, 707-725.	2.2	1
367	Circulating nucleosomes and elastase $\pm$ 1-antitrypsin complexes and the novel thrombosis susceptibility locus SLC44A2. <i>Thrombosis Research</i> , 2016, 142, 8-10.	1.7	1
368	Circulating activated protein C in thrombophilia carriers. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 361-364.	2.1	1
369	Low-Molecular-Weight Heparin and Recurrent Placenta-Mediated Pregnancy Complications: A Meta-analysis of Individual Patient Data From Randomised Controlled Trials. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 153-155.	0.4	1
370	Inherited Thrombophilia and Early Pregnancy. , 2017, , 234-246.		1
371	The risk of cesarean delivery after labor induction among women with prior pregnancy complications: a subgroup analysis of the AFFIRM study. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 455.	2.4	1
372	Thromboprophylaxis after renal transplantation and patient risk stratification: The case of mTOR inhibitors. <i>Thrombosis Research</i> , 2020, 195, 100-102.	1.7	1
373	Transgender health and haematologyâ€”a matter of respect. <i>Lancet Haematology</i> ,the, 2020, 7, e367.	4.6	1
374	Abstract P3: Andexanet Alfa for Acute Bleeding During Treatment With Edoxaban. <i>Stroke</i> , 2021, 52, .	2.0	1
375	Acute myocardial infarction with large bilateral intracoronary thrombi in a young patient with the prothrombin 20210 Gâ€™ &gt; A mutation. <i>Catheterization and Cardiovascular Diagnosis</i> , 1998, 44, 427-430.	0.3	1
376	A New Microparticle Coagulant Activity Assay to Predict Venous Thromboembolism in Patients with Pancreatic Cancer. <i>Blood</i> , 2014, 124, 4250-4250.	1.4	1
377	Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. <i>Blood</i> , 2016, 128, 2611-2611.	1.4	1
378	Pre-admission anticoagulant therapy and mortality in hospitalized COVID-19 patients: A retrospective cohort study. <i>Thrombosis Research</i> , 2021, 208, 35-38.	1.7	1



#	ARTICLE	IF	CITATIONS
379	Unsuspected Pulmonary Embolism in Cancer Patients: A Multicenter, International, Prospective, Observational Study. <i>Blood</i> , 2014, 124, 1546-1546.	1.4	1
380	Low Molecular Weight Heparin for Prevention of Placenta-Mediated Pregnancy Complications: An Individual Patient Data Meta-Analysis. <i>Blood</i> , 2015, 126, 890-890.	1.4	1
381	Effects of Andexanet Alfa on Thrombin Generation in Bleeding Associated with Factor Xa Inhibitors. <i>Blood</i> , 2019, 134, 711-711.	1.4	1
382	How to decide on the optimal duration of anticoagulation therapy in carriers of the factor V Leiden mutation. <i>Thrombosis and Haemostasis</i> , 2000, 84, 740-1.	3.4	1
383	6A.4 Debate: Antithrombotics for prevention of pregnancy loss – No. <i>Thrombosis Research</i> , 2007, 119, S76.	1.7	0
384	Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutation: reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 1992-1994.	3.8	0
385	Reliability of questionnaires on the use of thromboprophylaxis. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1042-1043.	3.8	0
386	No linkage for venous thrombosis at a candidate region on chromosome 18 in Dutch thrombophilic families. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1239-1240.	3.8	0
387	O18 High thrombin activatable fibrinolysis inhibitor (TAFI) levels may protect against recurrent early fetal loss. <i>Thrombosis Research</i> , 2009, 123, S136.	1.7	0
388	Inherited thrombophilia and early pregnancy. , 0, , 131-142.		0
389	Reproducibility Of Exhaled NO Measurements In Overweight Subjects. , 2010, , .		0
390	O.04a Risk of VTE during combined oral contraceptive use and pregnancy in women with mild thrombophilia. <i>Thrombosis Research</i> , 2011, 127, S124.	1.7	0
391	P-027 A male or female family history of VTE. Does it influence hormone-related VTE risk?. <i>Thrombosis Research</i> , 2013, 131, S83.	1.7	0
392	Prophylaxis for venous thromboembolism during asparaginase therapy in patients treated for acute lymphoblastic leukemia. <i>The Cochrane Library</i> , 0, , .	2.8	0
393	Inherited Thrombophilia and Pregnancy Loss. , 0, , 189-196.		0
394	Genes associated with venous thromboembolism in colorectal cancer patients. <i>Thrombosis Research</i> , 2018, 164, S228-S229.	1.7	0
395	O009: Safety and efficiency of the YEARS diagnostic algorithm for pregnant patients with clinically suspected acute pulmonary embolism: the ARTEMIS study. <i>Thrombosis Research</i> , 2019, 175, S3-S4.	1.7	0
396	Fever and a rapidly progressive skin ulcer after a visit to Morocco: A diagnostic challenge. <i>Travel Medicine and Infectious Disease</i> , 2019, 31, 101429.	3.0	0

#	ARTICLE	IF	CITATIONS
397	Outcome of intracranial bleeding managed with prothrombin complex concentrate in patients on direct factor Xa inhibitors or vitamin K antagonists. <i>Thrombosis Research</i> , 2020, 196, 404-409.	1.7	0
398	Diagnostic tests for pregnancy-related deep vein thrombosis. <i>The Cochrane Library</i> , 0, , .	2.8	0
399	Risk for Venous Thromboembolism in Carriers of the Factor V Leiden Mutation. <i>Annals of Internal Medicine</i> , 2003, 138, 76.	3.9	0
400	Is het zinvol een 60-jarige man met de factor-V-Leiden-mutatie profylactische te behandelen met acetylsalicylzuur?. , 2006, , 2198-2199.		0
401	Is Mirena® verantwoord bij een patiënte met een stollingsstoornis?. , 2006, , 2020-2021.		0
402	Current Practice of Testing for Hereditary Thrombophilia in the Netherlands.. <i>Blood</i> , 2006, 108, 3288-3288.	1.4	0
403	Evidence for QTLs Influencing the Endogenous Thrombin Potential (ETP) and Protein C Concentrations in a Dutch Family with Unexplained Thrombophilia.. <i>Blood</i> , 2007, 110, 132-132.	1.4	0
404	No Difference in Risk of Recurrent Venous Thrombosis between Men and Women. Results from a Family Cohort Study in 3356 Subjects.. <i>Blood</i> , 2007, 110, 130-130.	1.4	0
405	High Thrombin Activatable Fibrinolysis Inhibitor (TAFI) Levels May Protect against Recurrent Fetal Loss.. <i>Blood</i> , 2008, 112, 1815-1815.	1.4	0
406	Vrouwspecifieke Aspecten van Veneuze Trombo-Embolie. , 2011, , 113-127.		0
407	Circulating Nucleosomes and Neutrophil Activation As Risk Factors for Deep Vein Thrombosis. <i>Blood</i> , 2012, 120, 3387-3387.	1.4	0
408	Onderzoeksprotocol: cohortonderzoek. , 2013, , 27-31.		0
409	Bewijs toepassen op individuele patiënten. , 2014, , 163-174.		0
410	Towards Successful Implementation of Pharmacokinetic-Guided Prophylactic Dosing of Clotting Factor Concentrate in Hemophilia; The Doâ€™s and Donâ€™ts after Discrete Choice Experiment Analysis. <i>Blood</i> , 2014, 124, 5038-5038.	1.4	0
411	The Performance of the Original and Simplified Wells Scores in Combination with Age-Adjusted D-Dimer Testing in the Diagnostic Management of Pulmonary Embolism. <i>Blood</i> , 2016, 128, 2569-2569.	1.4	0
412	Circulating Activated Protein C in Thrombophilia Carriers. <i>Blood</i> , 2016, 128, 4948-4948.	1.4	0
413	Safety and Efficiency of the YEARS Diagnostic Algorithm for Pregnant Patients with Clinically Suspected Acute Pulmonary Embolism â€”the Artemis Study. <i>Blood</i> , 2018, 132, 419-419.	1.4	0
414	A Plasma-Based Assay to Measure the Susceptibility of Factor V(a) to Inhibition By TFPÎ±. <i>Blood</i> , 2018, 132, 1168-1168.	1.4	0

#	ARTICLE	IF	CITATIONS
415	Hokusai post-PE study: a follow-up study on long-term outcomes of pulmonary embolism in patients treated with edoxaban vs warfarin. , 2020, , .		0
416	Antithrombotic therapy for live birth in women with recurrent pregnancy loss: do not confound available high-level evidence. Human Reproduction, 2021, 37, 190-191.	0.9	0
417	Accurate and efficient non-invasive strategy for early identification of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism (InShape II study). European Heart Journal, 2020, 41, .	2.2	0
418	Hormone replacement therapy and arterial thrombotic disease. Thrombosis Research, 2005, 115 Suppl 1, 68-71.	1.7	0
419	Interrater agreement of two scales on the severity of anticoagulant-related major bleeding in patients with venous thromboembolism. Thrombosis Research, 2022, 216, 11-13.	1.7	0
420	Effect of polypharmacy on bleeding with rivaroxaban versus vitamin K antagonist for treatment of venous thromboembolism. Reply. Journal of Thrombosis and Haemostasis, 2022, 20, 1748-1749.	3.8	0